News | Cardiovascular Clinical Studies | November 19, 2018

New FDA Proposed Rule Alters Informed Consent for Clinical Studies

Proposed rule would allow Institutional Review Boards to waive or alter informed consent requirements for clinical studies that pose minimal risk to human participants under limited conditions

New FDA Proposed Rule Alters Informed Consent for Clinical Studies

November 19, 2018 — The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for certain FDA-regulated clinical investigations that present no more than minimal risk to human research participants.

If finalized, the proposed rule — an amendment of FDA’s regulations to implement a provision of the 21st Century Cures Act — would allow the Institutional Review Board (IRB) responsible for the review and approval of the research to waive or alter certain elements of informed consent, or to waive the requirement entirely, under limited conditions. To waive or alter informed consent under the proposal, the IRB would need to make findings that have been included in a Common Rule waiver provision for minimal risk research for decades. The Common Rule provision has provided appropriate safeguards to protect the rights, safety and welfare of individuals participating in certain minimal risk research for more than 25 years.

The FDA intends to withdraw its related 2017 guidance if this proposed rule becomes final. The agency is also seeking input on the types of minimal-risk clinical investigations for which sponsors or investigators would anticipate requesting a waiver or alteration of informed consent from the IRB.

The full proposed rule can be read here.

“Obtaining informed consent from those who volunteer to participate in research is a fundamentally important principle of human subject protection. The quality and integrity of clinical research is something the agency takes very seriously and the protection of research individuals is paramount. Over the years, we’ve received feedback from sponsors and investigators that they were not able to move forward in conducting important clinical investigations where there would be minimal risk as these trials involved situations where obtaining informed consent wasn’t possible, and the agency lacked the authority to permit a waiver of informed consent for that research. With the passage of the 21st Century Cures Act, the FDA’s authorities were changed, allowing greater flexibility. That’s why today, we’re proposing a change to our informed consent regulations in a way that maintains safeguards to protect study participants, while allowing important research to proceed where there is minimal risk to patients,” said FDA Commissioner Scott Gottlieb, M.D. “This change would facilitate the conduct of certain minimal risk clinical investigations that may be important to addressing significant public health needs without compromising the rights, safety, or welfare of human subjects.”

For more information: www.fda.gov


Related Content

Feature | Cardiovascular Business | By Christine Book

World Heart Day takes place each year on September 29. Founded in 2000 by the World Heart Federation, World Heart Day ...

Home September 28, 2022
Home
News | Cardiovascular Business

September 27, 2022 — Martha Gulati, MD, an expert in preventive cardiology and women’s heart disease, has joined the ...

Home September 27, 2022
Home
News | Cardiovascular Business

September 21, 2022 — MedAxiom, the premier source for cardiovascular organizational performance solutions, has released ...

Home September 21, 2022
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Here is a rundown of what you and your colleagues found to be most interesting in the fields of diagnostic and ...

Home September 07, 2022
Home
Feature | Cardiovascular Business | By Christine Book

As the cardiology community commemorates the importance of heart health on World Heart Day, Sept. 29, here’s a quick ...

Home August 18, 2022
Home
News | Cardiovascular Business

August 17, 2022 — Memorial Healthcare System, a South Florida-based academic medical center, has added a diverse trio of ...

Home August 17, 2022
Home
News | Cardiovascular Business

August 16, 2022 — A study of cardiology programs indicates that patients’ documented do-not-resuscitate (DNR) ...

Home August 16, 2022
Home
News | Cardiovascular Business

August 16, 2022 — Two leaders in cardiovascular disease science, research and education, the American Heart Association ...

Home August 16, 2022
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Diagnostic and Interventional Cardiology (DAIC) maintains more than 30 comparison charts of product specifications from ...

Home August 12, 2022
Home
News | Cardiovascular Business

August 12, 2022 — Clarius Mobile Health, a leading provider of high-definition wireless ultrasound systems, announced ...

Home August 12, 2022
Home
Subscribe Now